We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
(-0.95%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$2.85M |
| 2 |
Alphatec Holdings
ATEC
|
+$2.84M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$2.84M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$2.12M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$1.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$4.17M |
| 2 |
Pacira BioSciences
PCRX
|
+$3.36M |
| 3 |
Pfizer
PFE
|
+$3.06M |
| 4 |
United Therapeutics
UTHR
|
+$2.79M |
| 5 |
uniQure
QURE
|
+$2.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Enact Holdings
ACT
$6.49B
| $1.54M | 1.14% |
42,367
| – | – |
|
27
Equity Lifestyle Properties
ELS
$12.8B
| $1.47M | 1.09% |
20,611
| – | – |
|
|
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.46M | 1.09% |
20,000
| – | – |
|
29
Amphastar Pharmaceuticals
AMPH
$871M
| $1.46M | 1.08% |
30,000
+5,000
| +20% | +$219K |
|
|
VRNA
30
DELISTED
Verona Pharma
VRNA
| $1.44M | 1.07% |
50,000
-6,000
| -11% | -$148K |
|
31
GSK
GSK
$104B
| $1.43M | 1.06% |
35,000
| – | – |
|
|
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
| $1.37M | 1.02% |
+47,500
| New | +$1.76M |
|
|
ADAM
33
Adamas Trust
ADAM
$807M
| $1.27M | 0.95% |
200,963
| – | – |
|
|
RVNC
34
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.27M | 0.95% |
245,000
| – | – |
|
|
ONC
35
BeOne Medicines Ltd
ONC
$32.4B
| $1.23M | 0.92% |
5,500
-9,500
| -63% | -$1.71M |
|
36
Stereotaxis
STXS
$154M
| $1.22M | 0.91% |
600,000
| – | – |
|
37
Enovis
ENOV
$1.56B
| $1.18M | 0.88% |
27,500
+7,500
| +38% | +$334K |
|
38
Roivant Sciences
ROIV
$24.8B
| $1.15M | 0.86% |
100,000
+12,000
| +14% | +$137K |
|
39
Structure Therapeutics
GPCR
$3.45B
| $1.14M | 0.85% |
26,000
| – | – |
|
40
Takeda Pharmaceutical
TAK
$54.8B
| $1.14M | 0.85% |
+80,000
| New | +$1.13M |
|
41
Protagonist Therapeutics
PTGX
$9.06B
| $1.13M | 0.84% |
25,000
| – | – |
|
42
Perspective Therapeutics
CATX
$341M
| $1.07M | 0.79% |
80,000
-2,000
| -2% | -$26.6K |
|
43
Celldex Therapeutics
CLDX
$2.77B
| $1.02M | 0.76% |
30,000
-17,500
| -37% | -$667K |
|
|
44
Pfizer
PFE
$143B
| $1.01M | 0.75% |
35,000
-105,000
| -75% | -$3.06M |
|
45
Sanofi
SNY
$107B
| $1.01M | 0.75% |
17,500
| – | – |
|
46
Immunovant
IMVT
$8.27B
| $998K | 0.74% |
35,000
-1,500
| -4% | -$44.2K |
|
47
Lantheus
LNTH
$7B
| $988K | 0.73% |
+9,000
| New | +$935K |
|
48
Axsome Therapeutics
AXSM
$11.8B
| $944K | 0.7% |
10,500
-4,500
| -30% | -$393K |
|
49
Karyopharm Therapeutics
KPTI
$216M
| $934K | 0.69% |
75,000
| – | – |
|
50
AGNC Investment
AGNC
$12.9B
| $885K | 0.66% |
84,646
| – | – |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.
- AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
- AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
- AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
- AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
- AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
- AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
- AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.
Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.